Canada markets closed

PFE Jan 2026 47.500 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.28000.0000 (0.00%)
As of 02:29PM EDT. Market open.
Full screen
Previous Close0.2800
Expire Date2026-01-16
Day's Range0.2800 - 0.3000
Contract RangeN/A
Open Interest568

    Merck Prepares to Take on Pfizer After Pneumococcal Vaccine Approval

    Pfizer currently dominates the market for pneumococcal vaccines, which protect against bacterial infections that can cause pneumonia and meningitis, among other conditions. Merck, however, has been nipping at Pfizer’s heels for years. The company sells Vaxneuvance and Pneumovax 23, pneumococcal vaccines with combined 2023 revenue of $1.1 billion.

  • Business Wire

    Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts

    NEW YORK, June 18, 2024--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:30 a.m. EDT on Tuesday, July 30, 2024. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2024 Performance Report, to be issued that morning.

  • Zacks

    Merck's (MRK) 21-Valent Pneumococcal Jab Gets FDA Approval

    Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive/V116, becomes the first PCV specifically designed for adults to be approved by the FDA.